9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells

Norihiro Sato, Kazuhiro Mizumoto, Masahiro Kusumoto, Hideaki Niiyama, Naoki Maehara, Takahiro Ogawa, Masao Tanaka

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


There is increasing interest in identifying potent inhibitors of telomerase because the enzyme plays a crucial role in the development of cellular immortality and carcinogenesis. We hypothesized that 9-hydroxyellipticine (9-HE), an antitumor alkaloid, would inhibit telomerase activity because the drug has a unique mechanism of inhibiting phosphorylation of mutant p53 protein via inhibition of protein kinases, thereby restoring wild-type p53 function. This study was conducted to examine the effect of 9-HE on telomerase activity in human pancreatic cancer cells with differing p53 gene status. 9-HE treatment at relatively high concentrations resulted in rapid, complete inhibition of telomerase activity, irrespective of the p53 status. We conclude that 9-HE may exert a strong inhibitory effect on telomerase activity possibly through inhibition of protein kinases rather than through restoration of functional wild-type p53. Copyright (C) 1998 Federation of European Biochemical Societies.

Original languageEnglish
Pages (from-to)318-321
Number of pages4
JournalFEBS Letters
Issue number2
Publication statusPublished - Dec 18 1998
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Structural Biology
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Cell Biology


Dive into the research topics of '9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells'. Together they form a unique fingerprint.

Cite this